Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.Antimicrobial agents and chemotherapy · 1996
   Trial
2. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.Proceedings of the National Academy of Sciences of the United States of America · 1994
   Article
3. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.Proceedings of the National Academy of Sciences of the United States of America · 1994
   Article
4. Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).Drugs · 1993
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as